LYCovMab
Alternative Names: BA-4101; LY-CovMab; SARS-CoV2 spike protein antibody - Shandong Boan BiotechnologyLatest Information Update: 24 Feb 2023
At a glance
- Originator Shandong Boan Biotechnology
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 24 Feb 2023 Discontinued - Phase-I for COVID-2019 infections (Prevention) in China (Parenteral) (Shandong Boan Biotechnology pipeline, February 2023)
- 24 Feb 2023 Discontinued - Phase-II for COVID-2019 infections in China (Parenteral) (Shandong Boan Biotechnology pipeline, February 2023)
- 24 Feb 2023 Discontinued - Phase-II for COVID-2019 infections in USA (Parenteral) (Shandong Boan Biotechnology pipeline, February 2023)